Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
MedChem Buzz
Kilomentor
On Pharma
A New Merck, Reviewed
Liberal Arts Chemistry
One in Ten Thousand
Electron Pusher
Periodic Tabloid
All Things Metathesis
C&E News Blog
Propter Doc
Chemiotics II
The Chemical Notebook
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
Chirality
BBSRC/Douglas Kell
ChemBark
Drug Discovery Opinion
Realizations in Biostatistics
Chemjobber
Pharmalot
WSJ Health Blog
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Useful Chemistry
Chiral Jones
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Totally Synthetic
Fragment Literature
The F- Blog
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Carbon-Based Curiosities
Experimental Error
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Chemical Forums
Depth-First
Symyx Blog
P212121
ChemCafe
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Speculist
Cosmic Variance
The Capsule
Zeroth Order Approximation
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Drugs and Money | Main | Commenting Issues »

February 1, 2008

A Few Questions For My Fellow Pharma Chemists

Email This Entry

Posted by Derek

1. You’ve got a compound repository, right? Lots of vials, robot retrieval systems if you’ve got the cash, all that stuff? What fraction of those vials are full of sticky stuff that are colored warning shades of dark orange, red, or soy-sauce brown? And of those, what fraction has had colorfulness overtake it while in your repository racks, as opposed to the stuff that arrived looking that way? Bonus question: are you aware of any cranberry-red wonder drugs, and have you ever heard of anyone formulating a big manufacturing batch for Phase III while checking to make sure it’s the right shade of brown?

2. You’ve got some molecular modelers, right? And you ask them to try to dock some of your compound ideas into your favorite binding sites? OK, first question: how many times have any of them come back to you saying that they can’t fit something in? If the answer is “never”, you have a problem with your modelers. Second question: if you do get told that your compound doesn’t seem to dock, do you keep going down the hall until you find someone who can jam your idea into the model? In that case, the problem is closer to home.

3. You’ve got biologists on your project, right? In vitro assay people, then the in vivo group, ready to test whatever makes it that far? So, how much compound do they ask for? And how much of that do they plan to actually use? When they ask, how much compound do you tell them you have on hand (or can make)? And what fraction of what you really have or can make is that, exactly? Depending on the ratio between these various answers, you can either have no problems or you can be living with quite a few different ones simultaneously.

Comments (3) + TrackBacks (0) | Category: Life in the Drug Labs


COMMENTS

1. Moebius on February 1, 2008 2:02 PM writes...

Well, Rifamycins range from yellow to purple (with some red ones and blue ones). Making analogs of them, you get pretty cool looking TLC plates. And purifying is easy : just collect the colored stuff !

Permalink to Comment

2. weirdo on February 7, 2008 12:44 AM writes...

Not sure this isn't just disappearing into the ether, but:

1) About 5-8% are absolute crap. Of purchased molecules, about 25% came that way. Of internally prepared molecules, far less than 5%, I'd say. HOWEVER, about half of the internally prepared samples that have "gone off" should never have been submitted in the first place, no matter how pure they were -- for reasons you have posted on before!

2) Our modellers are pretty good at telling us molecules won't work. We tend to make a bunch of them anyway. Rather than consider this a "problem", however, I consider it very good practice. Negative data helps refine SAR too, and you're not pushing the boundaries if you only make molecules that you think SHOULD bind. (Yes, I know this sounds preachy, but it's a Sunday . . .). And I haven't worked on a project in years where making new analogues of the same core structures didn't eventually lead to a new, unpredicted binding mode.

3) At this point, we've trained our DISCOVERY biologists very well. They ask for what they actually need, plus 20% overage. We tend to tell them exactly how much we have, because we trust their judegement, and they understand the issues. It took about a year to get to this point, but that's where we are now. I note you didn't ask about toxicologists or formulations scientists though! Now THAT'S a whole 'nother ballgame! Never tell a toxicologist how many grams you think you can make!

Permalink to Comment

3. DANA on May 28, 2009 10:41 PM writes...

I was reading that the Red Bull Cola has been banned in Germany for containing cocaine or its matabolite benzoylecgonine. My problem is that I have been drinking it every day 2 to 4 cans per day for the last month. I have been drinking quite a bit because I have severe cluster headaches and the caffeine helps reduce the severity of the headache. Well I tested positive on a drug screen for cocaine and I know that is the only thing that would have caused it. I see that 1 can contain 0.13ug or 130ng per can and 0.4ug or 400ng per liter. Can you please help me find out who were the testing laboratory and a way of contacting them? I am a Police Officer and I’m also in the Military Reserves for 22 years, which I stand to loose every thing if I cannot prove that this beverage was the cause of my positive drug test. I do take benicar hct 40/25 and viagra but they don't cause positive results can u tell me if there is a way to calculate how much BE would be in a single 12 oz can given 1 can contains 130ng of cocaine. Was not given any test results guessing gc/ms was between 400-500ng. At least I was told 3 times he gc/ms cutoff. I also assisted narcotic officers 9 days before the test in which cocaine and crack were removed from the home, I was inside the home but I did not handle any of the drugs. But I did take two suspects to jail.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Academia and Industry, Suing Each Other
Let's Start Off the Meeting With An Ad, OK?
The Academic-Industrial Collaboration in Drug Discovery Panel: Today
Glass Structure, Atom by Atom
How the Andrulis Paper Got Published
AstraZeneca in Waltham
Fluorine NMR: Why Not?
AstraZeneca Layoffs and Closings